Breast Cancer Molecular Subtyping in Practice: A Real-World Study of the APIS Breast Cancer Subtyping Assay in a Consecutive Series of Breast Core Biopsies
Authors:
- Silvana Di PalmaSPSilvana Di Palma
- Panagiotis KoliouPKPanagiotis Koliou
- Alex SimonovicASAlex Simonovic
- Daniela CostaDCDaniela Costa
- Catherine FaulkesCFCatherine Faulkes
- Brenda KobutungiBKBrenda Kobutungi
- Felicity PatersonFPFelicity Paterson
- Jonathan David HorsnellJHJonathan David Horsnell
- Farrokh PakzadFPFarrokh Pakzad
- Tracey IrvineTITracey Irvine
- Polly PartlettPPPolly Partlett
- Elizabeth ClaytonECElizabeth Clayton
Open Access
- 23 February 2024
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (5) , 2616
Abstract
The APIS Breast Cancer Subtyping Kit is an mRNA-based assessment of the seven parameters including three biomarkers routinely assessed in all the newly diagnosed breast cancers (BC), oestrogen receptor (ER), progesterone receptor (PR) and HER-2 and an additional four genes that create a novel proliferation signature, MKI67, PCNA, CCNA2 and KIF23. Taken together, the data are used to produce a molecular subtype for every sample. The kit was evaluated against the current standard protocol of immunohistochemistry (IHC) and/or in situ hybridisation (ISH) in breast cancer patients. The data were presented at the weekly breast multidisciplinary team (MDT) meeting. A total of 98 consecutive cases of pre-operative breast cancer core biopsies and two core biopsies of nodal metastases yielding 100 cases were assessed. IHC and APIS results were available for 100 and 99 cases. ER was concordant in 97% cases, PR was concordant in 89% and HER-2 results were concordant with IHC/ISH in 100% of the cases. Ki-67 IHC was discordant in 3% of cases when compared with MK167 alone but discordant in 24% when compared with the four-gene proliferation signature. In conclusion, our study indicates that the APIS Breast Cancer Subtyping Kit is highly concordant when compared to the results produced for ER/PR/HER-2 by IHC and/or ISH. The assay could play a role in the routine assessment of newly diagnosed breast cancer (BC) specimens.Keywords
All Related Versions
Funding Information
- APIS BC Subtyping group
This publication has 20 references indexed in Scilit:
- The SP/NK1R system promotes the proliferation of breast cancer cells through NF-κB-mediated inflammatory responsesCell Biochemistry and Biophysics, 2023
- Concordance of HER2-low scoring in breast carcinoma among expert pathologists in the United Kingdom and the republic of Ireland –on behalf of the UK national coordinating committee for breast pathologyThe Breast, 2023
- Improving mitotic cell counting accuracy and efficiency using phosphohistone‐H3 (PHH3) antibody counterstained with haematoxylin and eosin as part of breast cancer gradingHistopathology, 2022
- Upregulated cyclins may be novel genes for triple-negative breast cancer based on bioinformatic analysisBreast Cancer, 2020
- Identification of core genes and potential molecular mechanisms in breast cancer using bioinformatics analysisPathology - Research and Practice, 2019
- An International Ki67 Reproducibility StudyJNCI: Journal of the National Cancer Institute, 2013
- Salivary duct carcinomas can be classified into luminal androgen receptor‐positive, HER2 and basal‐like phenotypes*Histopathology, 2012
- PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancerBreast Cancer Research and Treatment, 2012
- Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care?Nature Reviews Cancer, 2007
- Molecular portraits of human breast tumoursNature, 2000